Moody's Investors Service has just withdrawn its provisional rating of 'Baa2 (sf)' on the secured notes, Series 2011-1 that were to be issued by Drug Royalty LP 1, a subsidiary of Toronto-based DRI Capital. Credit Suisse is lead managing the deal.

The $200 million securitization was backed by 18 drug royalty streams generated from the global sales of 14 drugs. The deal is comprised of Class A-1 floating-rate notes and Class A-2 fixed-rate notes, which rank pari-passu for all purposes.

Subscribe Now

Access to a full range of industry content, analysis and expert commentary.

30-Day Free Trial

No credit card required. Access coverage of the securitization marketplace, including breaking news updated throughout the day.